Aller au contenu

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

Nom du journal : Eur J Cancer

Année : 2020

Volume : 134

Page de départ : 62

Page de fin : 74

Auteurs: Kopeckova K, Zaffaroni F, Dileo P, Nzokirantevye A, Kasper B, Benson C, Mir O, Cousin S, Gelderblom H, Litière S, Papai Z, Wozniak A, Wardelmann E, Marréaud S, Italiano A, Blay JY, Le Cesne A, Schöffski P, Ali N, Menge F, Vanden Bempt I,